

Identification of Common Mutations Causing Wilson Disease in Egyptian Children

*Thesis Submitted for partial fulfillment of MD degree in clinical and
chemical pathology
By*

Marwa Mahmoud Abdel-Aziz Alsharkawy

M.B.B.Ch, MSc

Supervisors

Prof. Dr Fatma El Mougy

Professor of Clinical & Chemical Pathology

Faculty of Medicine-Cairo University

Prof. Dr Hanaa El karaksy

Professor of Pediatric

Faculty of Medicine-Cairo University

Prof. Dr Iman Atef Mandour

Professor of Clinical & Chemical Pathology

Faculty of Medicine-Cairo University

Dr Riham El Essawy

Assistant Professor of Clinical & Chemical Pathology

Faculty of Medicine-Cairo University

Faculty of Medicine

Cairo University

2012

Abstract

Wilson Disease is caused by excessive accumulation of copper in hepatic and extrahepatic tissues due to defective excretion of copper into bile. As a result, copper accumulates particularly in the liver, kidney, brain, and cornea.

ATP7B gene, is responsible for transport of copper into bile from hepatocytes and its incorporation into apoceruloplasmin to form ceruloplasmin.

Wilson Disease is an autosomal recessive disorder, with high frequency in certain ethnic groups. Early diagnosis is mandatory to initiate early treatment so as to prevent morbidity and mortality.

Clinical features are highly variable, so the diagnosis may be easily missed. This is especially critical since the disease is readily treatable by chelating agents such as penicillamine or trientine, or by oral zinc that blocks copper absorption.

Key Words:

Elution buffer - base pair – Identification .

Acknowledgement

“He, and will always be, Allah who always blessed my work

And who sent me those who were of help “

*In the first place, I would like to express my sincere appreciation and full gratitude to my supervisor **Dr. Fatma Elmogy** professor of Clinical and Chemical Pathology, Cairo University, I am indebted to my supervisor for her strict supervision of this work, she gave me much of her time, experience and support. Her motherhood attitude and encouragement were so supportive for the completion of this work.*

*My deep thanks and appreciation to **Dr. Hanaa El-karaksy**, Professor of pediatric medicine, Cairo University for her constant encouragement, valuable advices and support that cannot be expressed in words.*

*I would especially like to thank **Dr. Iman Mandour**, Professor of Clinical and Chemical Pathology, Cairo University, for her kindness, generous help, goodness and her strict revision of this work, sincere encouragement and patience with me.*

*I would like to thank, **Dr. Riham El Essawy**, Assistant Professor of Clinical and Chemical Pathology, Cairo University for her help and support throughout the work.*

*I would like to thank **Dr. Nehad Mosaad** Professor of Clinical and Chemical Pathology and **Dr. Abeer Mohey** Assistant Professor of Clinical and Chemical Pathology, Cairo University, for their help, advice and support.*

*I would like to thank the members of the Al Kasr Al-Aini Research Lab, who made the lab an enjoyable place to work specially **Dr. Sahar Abd AlAtti** Professor of Clinical and Chemical Pathology, Cairo University, for her intellectual contributions, friendship and generous support.*

I am grateful for all that I have learned from. I would also like to thank everyone in the Color for Research lab.

I would like to address my full recognition to my all staff members of Clinical and Chemical pathology Department, Cairo University, for all their time, suggestions and scientific contributions.

I thank all of the patients and their families who provided samples for our studies.

Finally, I would like to dedicate this thesis to the most wonderful gifts I had in this life, to my family, specially my parents, for without their support, encouragement and confidence in my abilities; I would not have accomplished this goal. I would like to thank my sister for her continuous support. I owe special gratitude to my husband for his continuous and unconditional support, to my daughter Habiba and my son Mohamed.

Marwa El-Sharkawy

Table of contents

Introduction and aim of the work.....	1
Review of literature.....	
-<u>Chapter I:</u> Wilson Disease.....	3
- <u>Chapter II:</u> Genetics of Wilson disease.....	29
Subjects and Methods.....	42
Results.....	67
Discussion.....	79
Summary and Conclusions.....	88
Appendices.....	92
References.....	112
.....الملخص العربي	

List of Table

Table 1	Scoring system developed at the 8th International Meeting on Wilson's disease, Leipzig 2001	24
Table 2	New Wilson Index for Predicting Mortality	25
Table 3	Available treatments for WD	26
Table 4	The primers sequence and the protocol of amplification	48
Table 5	The protocol of cycle sequencing	56
Table 6	Clinical and laboratory data of the 10 unrelated cases	64
Table 7	Clinical and laboratory data of the 10 cases with their families (7a-7f)	65-67
Table 8	Sequence variants detected in the study	69
Table 9	Frequency of non disease-causing variants	69

Table 10	Frequencies of sequence variants detected in the study	71
Table 11	Results of mutational analysis, clinical presentation and outcome of the 8 WD cases	27
Table 12	Comparison between different mutations reported in the study and the clinical data of the studied cases.	73
Table 13	The genetic code	97
Table 14	The nucleotides symbols	97
Table 15	Amino acid nomenclature	99
Table 16	Amino acid properties.	100

List of figures

Figure 1	Copper distribution in the body	6
Figure 2	Copper metabolism	9
Figure 3	Illustrates the location of the ATP7B gene on Chromosome 13	31
Figure 4	Wilson disease protein	35
Figure 5	WD gene showing the site of common mutations	36
Figure 6	QIAamp Spin Procedure	45
Figure 7	The amplified products (exon 14) appear as a single band of 182 bases	53
Figure 8	Separation principle	58
Figure 9	Chart of mean age of presentation	62

Figure 10	The frequency of presentation of the disease in the studied cases	63
Figure 11	Pedigree of Family 1	74
Figure 12	Sequencing results for exon 14	75
Figure 13	Pedigree of Family 2	76
Figure 14	Pedigree of family 3.	77
Figure 15	The sequence of a part of exon 14 show heterozygous mutation (c.3364C>A)	78
Figure 16	Pedigree of family 4	79
Figure 17	The sequence of a part of exon 18	80
Figure 18	Pedigree of family 5	81
Figure 19	Pedigree of family 6	82

List of abbreviations

- **AASLD:** American Association for the Study of Liver Diseases.
- **ATOX1:** Antioxidant protein 1.
- **ATP7B:** Adenosine triphosphate.
- **BI-PASA:** Bidirectional PCR amplification of specific alleles.
- **Buffer AE:** Elution buffer.
- **Buffer AL:** Lysis buffer.
- **Buffer AW:** washing buffer.
- **Bp:** base pair.
- **CCS:** Copper chaperone of superoxide dismutase.
- **CMT1, CTR1:** Copper membrane transporter 1.
- **COX:** Cytochrome-c oxidase.
- **CVS:** Chorionic villous sampling.
- **ddNTPs:** dideoxynucleotide triphosphates
- **dNTPs:** deoxynucleotide triphosphates.
- **EDTA:** Ethylene diammine tetraacetate.
- **ICC:** Indian childhood cirrhosis .
- **ID:** Identification.
- **Kb:** Kilobase, Unit of length for DNA fragments equal to 1000 nucleotides.
- **KF rings:** Kayser-Fleischer rings .
- **KRT8:** Keratin8 gene.
- **KRT18 :**Keratin18 gene.
- **NAFLD:** Nonalcoholic fatty liver disease.

- **PCR:** Polymerase chain reaction.
- **POP:** Performance Optimized Polymers.
- **ROS:** Reactive oxygen species.
- **Rpm:** Revolutions per minute.
- **SOD1:** Superoxide dismutase.
- **TGN:** Trans-Golgi network.
- **TE buffer:** Tris-HCl EDTA.
- **USA:** United States of America.
- **WD:** Wilson disease.

Introduction

Introduction

Copper is an essential metal that is an important cofactor for many proteins, the liver utilizes some copper for metabolic needs, synthesizes and secretes the copper-containing protein ceruloplasmin, and excretes excess copper into bile (**Roberts and Schilsky, 2008**).

Wilson disease (WD) is a recessive disorder of copper transport, in which the incorporation of copper into ceruloplasmin and excretion of copper through the bile are impaired. As a result, copper accumulates particularly in the liver, kidney, brain, and cornea. Clinical features are highly variable, so the diagnosis is easily missed. This is especially critical since the disease is readily treatable by chelating agents such as penicillamine or trientine, or by oral zinc that blocks copper absorption (**Cox and Roberts, 2006**).

The WD disease gene encodes ATP7B copper transporter, a gene of 21 exons, spanning approximately 100 kb. The 4.3 kb open reading frame encodes a 1,465 amino acid protein with features characteristic of the P-type ATPases (**Bull et al., 1993 and Tanzi et al., 1993**).

Mutational analyses of WD patients and their relatives have identified more than 518 distinctive variants as reported in the WD mutation database. Most of these variants are probable disease-causing variants (379 out of 518 variants). The remaining variants are reported as possible normal variants (**Kenney and Cox, 2007**).

It was hypothesized that the mutations tend to occur in a population-specific manner. Some mutations appear to be population specific, whereas others are common in many populations (**Wu et al., 2001**).

The diagnosis of WD is based on the results of several clinical and biochemical tests, each has its limitations, and only the combination of clinical, biochemical and genetic tests provides a powerful and reliable tool for the diagnosis (**Merle et al., 2007**).

In Egypt, where viral hepatitis (HCV, HBV) is by far the major player in the field of liver disease, WD seems to be under diagnosed and clinical data on large cohorts are limited owing to its low frequency, being a rare disease. Increasing awareness about diagnosis and management based on detection of the mutational spectrum as a rapid screening approach may be applied for Egypt in the future (**El Karaksy et al., 2011**)

The aim of this study is to identify mutations in ATP7B gene in Egyptian diseased children by genetic study for early diagnosis and implementation of effective treatment before the onset of clinical symptoms. Also, help screening other family members to identify at risk individuals with presymptomatic gene mutation carriers.

\

Review of Literature